Simcere Pharmaceutical Group(SCR)- NYSE
SCR is defunct.
  • Aug. 28, 2013, 7:20 AM
    • China's Simcere Pharmaceutical (SCR) has agreed to be taken private by a consortium that includes founder and Chairman Jinsheng Ren in a deal worth $495.4M.
    • The buyout group, which already owns 78% of the company, is offering $9.66 per ADS, or a premium of 3% to the company's close of $9.36 yesterday. The price is also above a previous offer of $9.56. (PR)
    | Aug. 28, 2013, 7:20 AM
  • Mar. 11, 2013, 8:29 AM

    Simcere Pharmaceutical (SCR) jumps 16.2% to $9.25 after the Chinese company receives a buyout offer of $9.56/ADS from a consortium led by its chairman, Jinsheng Ren. The bid represents a premium of 19% on Simcere's Friday close of $7.96 and values the firm at $500M. The firm has appointed a committee of independent directors to analyze the offer. (PR)

    | Mar. 11, 2013, 8:29 AM
Company Description
Simcere Pharmaceutical Group is engaged in the research, development, manufacture and distribution of pharmaceutical products in the People's Republic of China.
Sector: Healthcare
Industry: Drug Manufacturers - Other
Country: China